Atlassian stock surged 4.1% after Jefferies analyst Brent Thill initiated coverage with a buy rating. Despite a 73% decline over the past 52 weeks, Thill argues that AI-generated code will increase demand for IT collaboration tools, positioning Atlassian to grow 20% annually. Trading at a 14.5x price-to-free cash flow ratio with strong fundamentals, the analyst views the stock as undervalued.

Upstart, an AI-powered fintech lending platform, has underperformed since its IPO with volatile stock performance and struggles due to rising interest rates and management uncertainty. The article recommends Jefferies Financial Group as a better alternative, citing strong M&A activity tailwinds, reasonable valuation metrics, and 42% upside potential from Wall Street analysts.

SOLV Energy, a leading infrastructure services provider to the power industry, priced its IPO at $25.00 per share for 20.5 million shares, with an additional 3.075 million share option for underwriters. The company will begin trading on Nasdaq under ticker 'MWH' on February 11, 2026, with closing expected February 12, 2026.

SpyGlass Pharma, a late-stage biopharmaceutical company focused on long-acting drug delivery for chronic eye conditions, priced its initial public offering at $16 per share, raising approximately $150 million. The company's common stock is expected to begin trading on Nasdaq under ticker symbol 'SGP' on February 6, 2026, with the offering closing on February 9, 2026.

The article recommends two financial stocks from Berkshire Hathaway's portfolio as strong buys in February: Ally Financial and Jefferies Financial Group. Ally has streamlined its business by exiting low-growth segments, improving credit quality and margins ahead of expected rate cuts. Jefferies, a pure-play investment bank, has recovered from a 19% stock decline caused by First Brands bankruptcy exposure and stands to benefit from a strong M&A market in 2026.

Ford Motor and General Motors are in advanced discussions to provide a financial lifeline to bankrupt auto parts supplier First Brands Group through advance payments for future product deliveries. The Ohio-based supplier, which produces critical components including windshield wiper parts for Ford's F-150, filed for bankruptcy in September 2025 with nearly $12 billion in debt. While talks are near completion, the deal remains uncertain, with Ford facing the highest exposure risk.

Christopher Wood, global head of equity strategy at Jefferies Financial Group, has removed Bitcoin from his model portfolio and replaced it with gold and gold stocks due to concerns that quantum computing could pose an 'existential' threat to Bitcoin's security sooner than many developers expect. While Bitcoin developers estimate 5-10+ years before quantum computers could break Bitcoin's encryption, Wood believes it could happen within years. About 4 million bitcoins (25% of all coins) worth ~$370 billion could be vulnerable to quantum attacks.

First Solar stock dropped over 10% after analyst Julian Dumoulin-Smith downgraded the company from buy to hold, reducing his price target from $269 to $260 per share. The downgrade was driven by concerns about persistent debookings (customer project cancellations), management's repeated guidance reductions, and limited government support for alternative energy following the passage of the Big, Beautiful Bill.

Pomerantz LLP is investigating Jefferies Financial Group for potential securities fraud related to its Point Bonita Capital asset management unit's $715 million exposure to bankrupt auto supplier First Brands. The investigation follows First Brands' bankruptcy amid accounting questions, a DOJ inquiry, and an SEC investigation into whether Jefferies adequately disclosed investor exposure to First Brands. Jefferies' stock fell 7.88% on October 8, 2025, following the initial disclosure.

Travere Therapeutics stock surged nearly 14% on Wednesday following bullish analyst notes. Jefferies analyst Maury Raycroft identified Travere as a potential takeover candidate and highlighted its drug Filspari as having blockbuster potential. Cantor Fitzgerald reported that the FDA appears flexible on approving Filspari for treating focal segmental glomerulosclerosis (FSGS), with an FDA decision expected by January 13, 2026.

BlackSky Technology stock surged 14.13% after investment bank Jefferies initiated coverage with a 'buy' rating and a $23 price target, which the stock hit within 10 minutes. Jefferies projects BlackSky's new satellite constellation could drive 25% annual revenue growth, potentially reaching $211 million by 2028 and eventually exceeding $400 million annually with EBITDA margins above 65%.

D-Wave Quantum (QBTS) has surged 200% in 2025, though it has declined 50% from its October peak. The company's Advantage2 quantum annealing system offers differentiation in optimization and sampling problems. Wall Street analysts project 73% compound annual revenue growth through 2030. With $800M+ in cash and minimal debt, D-Wave is positioned to weather slow customer adoption, though technology adoption remains a key risk.